Davide Rossi

Ente Ospedaliero Cantonale — Switzerland

Medicine · Health Sciences

85h-index28.4kcitations1.1kworks1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(640), Lymphoma Diagnosis and Treatment(479), Immunodeficiency and Autoimmune Disorders(149), Cutaneous lymphoproliferative disorders research(80), Cancer Genomics and Diagnostics(78)

Publications1.1k total

Dual targeting of BTK and BCL2 enhances apoptosis in marginal zone lymphoma models: preclinical activity of BGB-16673 and sonrotoclax
2025Open Access
Integrated multi-omic profiling reveals two biologically distinct subgroups of splenic marginal zone lymphoma with prognostic relevance
Blood·2025
Survival differences of patients with treatment-naive CLL between the chemoimmunotherapy and BTKi eras: An eric study.
Blood·2025
CD49d expression is epigenetically regulated in chronic lymphocytic leukemia: Insights from CD49d bimodal cases
Blood·2025Open Access
Multilayer profiling of MRD in patients with relapsed/refractory CLL treated with venetoclax-based regimens in a real-world setting
Blood·2025Open Access
Clinical impact of untargeted baseline plasma metabolomics in newly diagnosed diffuse large B-cell lymphoma
Blood·2025Open Access
Real-world treatment patterns and outcomes in patients with CLL and cardiovascular comorbidities: Interim analysis of the multicenter study conducted by eric.
Blood·2025Open Access
Un raro caso: ittiosi di Arlecchino neonatale
Medico e Bambino pagine elettroniche·2025
High-Throughput Screening Identifies PLK1 Inhibition as a Strategy to Potentiate BTK Blockade in Marginal Zone Lymphoma
2025
Abstract C024: CBP/EP300 inhibitor OPN-6602 in marginal zone lymphomas: preclinical activity as a single agent and in combination with BTK inhibition
Molecular Cancer Therapeutics·2025
Abstract C023: Development of isogenic models of marginal zone lymphoma for therapeutic target discovery in TET2-deficient disease
Molecular Cancer Therapeutics·2025
Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography?
Journal of Clinical Oncology·2025· 1 cited
POSTER: CLL-1206 Prevalence and Clinical Impact of Clonal Hematopoiesis in Chronic Lymphocytic Leukemia
Clinical Lymphoma Myeloma & Leukemia·2025
CLL-1206: Prevalence and Clinical Impact of Clonal Hematopoiesis in Chronic Lymphocytic Leukemia
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: ABCL-900 Integration of [18F]FDG-Pet Radiomics With Liquid Biopsy Improves Outcome Prediction in Newly Diagnosed Diffuse Large B Cell Lymphoma
Clinical Lymphoma Myeloma & Leukemia·2025
ABCL-900: Integration of [18F]FDG-Pet Radiomics With Liquid Biopsy Improves Outcome Prediction in Newly Diagnosed Diffuse Large B Cell Lymphoma
Clinical Lymphoma Myeloma & Leukemia·2025
Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B-cell lymphoma models
2025Open Access
Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma
Leukemia·2025· 7 citedOpen Access
HMR-NEureka: Hybrid Modular Redundancy DNN Acceleration in Heterogeneous RISC-V SoCs
2025
PCR91 Patient Reported Outcomes in BRUIN CLL-321: A Phase 3 Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Value in Health·2025· 1 citedOpen Access
page 1 of 54Next →

Frequent Co-authors

Gianluca Gaïdano(39), Valter Gattei(16), Valeria Spina(16), Silvia Rasi(15), Roberto Marasca(15), Francesco Bertoni(14), Robin Foà(14), Laura Pasqualucci(13), Raúl Rabadán(11), Riccardo Dalla‐Favera(11), Francesco Forconi(11), Clara Deambrogi(11), Silvia Deaglio(11), Sara Monti(10), Alessio Bruscaggin(10), Michaela Cerri(9), Marco Fangazio(8), Stefania Cresta(8), Luca Laurenti(8), Giorgio Inghirami(8)